We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease (GAP-PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01850381
Recruitment Status : Completed
First Posted : May 9, 2013
Last Update Posted : August 8, 2019
Sponsor:
Collaborator:
Columbia University
Information provided by (Responsible Party):
Genervon Biopharmaceuticals, LLC

Tracking Information
First Submitted Date  ICMJE May 7, 2013
First Posted Date  ICMJE May 9, 2013
Last Update Posted Date August 8, 2019
Study Start Date  ICMJE June 2013
Actual Primary Completion Date July 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 31, 2019)
The change from the mean total UPDRS score of the combined screening and baseline visits to the total UPDRS score at the Week-12 visit, comparing treated with placebo.Compare safety and tolerability with placebo. [ Time Frame: Baseline, week 2, week 6, week 12 ]
Measure UPDRS and the change from the mean total UPDRS score of the combined screening and baseline visits to the total UPDRS score at the Week-12 visit, comparing treated with placebo.Compare safety and tolerability with placebo.
Original Primary Outcome Measures  ICMJE
 (submitted: May 8, 2013)
The change from the mean total UPDRS score of the combined screening and baseline visits to the total UPDRS score at the Week-12 visit, comparing treated with placebo.Compare safety and tolerability with placebo. [ Time Frame: Baseline, week 2, week 6, week 12 ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 31, 2019)
  • Change in total UPDRS between the mean screening-baseline visits and end of Week 2 (at visit 6 after dosing), and week 6, comparing the two arms of the study encompassing the entire cohort of 6 subjects. [ Time Frame: Baseline, week 2, week 6 ]
    Measure UPDRS and the Change in total UPDRS between the mean screening-baseline visits and end of Week 2 (at visit 6 after dosing), and week 6, comparing the two arms of the study encompassing the entire cohort of 6 subjects.
  • Change in UPDRS sub-scores (Mental, Activities of Daily Living, Motor) between the mean screening-baseline visits and ends of Week 2 (at visit 6 after dosing), 6, and 12, comparing the two arms of the study encompassing the entire cohort of 6 subjects. [ Time Frame: Baseline, week 2, week 6, week 12 ]
    Measure UPDRS subscores and the Change in UPDRS sub-scores (Mental, Activities of Daily Living, Motor) between the mean screening-baseline visits and ends of Week 2 (at visit 6 after dosing), 6, and 12, comparing the two arms of the study encompassing the entire cohort of 6 subjects.
  • Time to the development of sufficient disability to require a change in symptomatic therapy. [ Time Frame: 12 weeks ]
    Measure the Time to the development of sufficient disability to require a change in symptomatic therapy.
  • Proportion of subjects requiring additional symptomatic treatment due to disability. [ Time Frame: 12 weeks ]
    Measure the proportion of subjects requiring additional symptomatic treatment due to disability.
  • Change in Schwab & England ADL (activity of daily living) score from baseline to Week 2 (at visit 6 after dosing), 6, or 12. [ Time Frame: Baseline, week 2, week 6, week 12 ]
    Measure Schwab & England ADL score and its change from baseline to Week 2 (at visit 6 after dosing),
  • Change in Hoehn & Yahr score (H&Y), Beck Depression Inventory (BDI), and Montreal Cognitive Assessment (MOCA) scores from baseline to Week 2 (at visit 6 after dosing), 6, or 12. [ Time Frame: Baseline, week 2, week 6, week 12 ]
    Measure Hoehn & Yahr score (H&Y), Beck Depression Inventory (BDI) and MontrealCognitive Assessment (MOCA) scores and their changes from baseline to Week 2, Week 6 and Week 12
Original Secondary Outcome Measures  ICMJE
 (submitted: May 8, 2013)
  • Change in total UPDRS between the mean screening-baseline visits and end of Week 2 (at visit 6 after dosing), and week 6, comparing the two arms of the study encompassing the entire cohort of 6 subjects. [ Time Frame: Baseline, week 2, week 6 ]
  • Change in UPDRS sub-scores (Mental, Activities of Daily Living, Motor) between the mean screening-baseline visits and ends of Week 2 (at visit 6 after dosing), 6, and 12, comparing the two arms of the study encompassing the entire cohort of 6 subjects. [ Time Frame: Baseline, week 2, week 6, week 12 ]
  • Time to the development of sufficient disability to require a change in symptomatic therapy. [ Time Frame: 12 weeks ]
  • Proportion of subjects requiring additional symptomatic treatment due to disability. [ Time Frame: 12 weeks ]
  • Change in Schwab & England ADL score from baseline to Week 2 (at visit 6 after dosing), 6, or 12. [ Time Frame: Baseline, week 2, week 6, week 12 ]
  • Change in Hoehn & Yahr score (H&Y), Beck Depression Inventory (BDI), and Montreal Cognitive Assessment (MOCA) scores from baseline to Week 2 (at visit 6 after dosing), 6, or 12. [ Time Frame: Baseline, week 2, week 6, week 12 ]
Current Other Pre-specified Outcome Measures
 (submitted: July 31, 2019)
Secondary analyses will consider a comparison of slopes using a mixed-model approach with treatment as a fixed effect and subject-specific slopes as a random effect. [ Time Frame: 12 weeks ]
Measure the slopes of UPDRS change
Original Other Pre-specified Outcome Measures
 (submitted: May 8, 2013)
Secondary analyses will consider a comparison of slopes using a mixed-model approach with treatment as a fixed effect and subject-specific slopes as a random effect. [ Time Frame: 12 weeks ]
 
Descriptive Information
Brief Title  ICMJE Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease
Official Title  ICMJE GM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson Disease
Brief Summary

GM608 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system. The study drug is an oligopeptide with a sequence identical to one of the active sites of human Motoneuronotrophic Factor and is manufactured by solid phase synthesis. Preclinical research indicates it to be a neuro-protective agent in animal models of PD, other neuro-degenerative diseases and stroke. This trial is designed to test proof of principle, i.e. determine if a 2-week treatment with this agent can restore the non-functioning nigral dopaminergic neurons in PD over a 3 month period, during which the placebo-treated arm is expected to have little or no worsening of the total UPDRS (Unified Parkinson's Disease Rating Scale)score compared to baseline.

Study Objectives are:

  1. To compare the safety and tolerability of GM608 with placebo in a population of patients with early PD.
  2. To field test the study procedures for feasibility and efficiency
  3. To determine if there is any hint that injections of GM608 might slow the rate of clinical worsening of PD.
Detailed Description

Background The investigational drug GM608 is a synthetic oligopeptide containing 6 amino acids with a sequence identical to one of the active sites of human Motoneuronotrophic factor (MNTF), also referred to as GM6 in studies. MNTF is a novel human endogenous developmental stage neurotrophin for the nervous system with a specific human chromosome location.

The investigators' preclinical animal study has shown that intravenously injected GM608 is able to penetrate the blood-brain barrier and enter the brain. GM608 has shown neuroprotection in a variety of in vitro and animal models of numerous Central Nervous System (CNS) diseases including ischemic stroke, spinal cord injury, Parkinsons Disease (PD), amyotropic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer's Disease (AD) and Huntington Disease (HD). In particular, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) mouse model for PD all showed GM608 has neuroprotective effect. GM608 also enhanced neuron cell survival very significantly in the cerebrospinal fluid (CSF) of patients with Huntington disease, MS, Stroke, Parkinson, Alzheimer and ALS.

This pilot trial is designed to test proof of principle, i.e. determine if a 2-week treatment with this agent can restore the nonfunctioning nigral dopaminergic neurons in PD over a 3month period, during which the placebo-treated arm is expected to have little or no worsening of the total UPDRS score compared to baseline. A Phase 1 Clinical Trial Study has been completed. The Phase 1 Trial primary objective is to determine the safety and tolerability and to establish the pharmacokinetic and pharmacodynamic properties of GM608 at 0.5, 1.5, and 5.0 mg/kg administered as a single bolus intravenous dose in human subjects and after 3 consecutive daily doses of GM608 at the highest safe and tolerated dose of 5.0 mg/kg. The Phase 1 study established that 3 consecutive daily doses of 5.0 mg/kg of GM602 are safe and tolerated.

Mechanism of Action Motoneuronotrophic factor (MNTF) is highly specific to the human nervous system. It is expressed rapidly during the first trimester of human fetal development, peaking at week nine. MNTF is a developmental stage regulatory (antisense) neuro-signaling molecule that binds perfectly on very specific receptors. Using In Silico Analysis, Genervon identified and developed as a drug candidate one of the active sites of MNTF, an analog of six amino acids named GM608.

In the investigators' testing for efficacy in Parkinson disease MPTP and 6-OHDA animal models, GM608 demonstrated a dose dependent attenuation of PD in the mice with 20 mg/kg showing the most efficacious. Behavioral, biochemical and histological analysis demonstrated the attenuation illustrating a unique effect for GM608 in PD. These data suggest that GM608 is effective in the mouse model of PD following IV injection and may be a potential treatment for PD patients.

In the investigators' in vitro study in Parkinson disease, treatment with wortmannin (PI3K inhibitor) abrogated the protective effects of GM608 on SH-SY5Y (a neuroblastoma cell line popular in studying neuroscience) cells which were subjected to salsolinol exposure for 24 hours. The results suggested that GM608 may function through the phosphatidylinositol 3-kinase (PI3K) pathway which is an important pathway in neuronal diseases.

Although the neuroprotective mechanism in each of the animal studies is not well understood, the investigators hypothesize that GM608 respond to specific distress signal anywhere from the human nervous system through a common underlying mechanism by triggering specific pathway(s), possibly through the PI3 pathway and other pathways that protect neural tissues by increasing or decreasing specific gene(s) expressions.

This is a single-center, prospective, randomized, double-blind, and placebo-controlled pilot study, involving 6 subjects not on any dopaminergic medication (i.e. levodopa or dopamine agonist). Subjects will be randomized 2:1 into one of two treatment arms: (1) 4 subjects will receive i.v. injections of GM608 and (2) 2 subjects will receive a matching placebo. Progression of clinical PD will be assessed using the UPDRS over 12 weeks. Safety and tolerability will also be compared between treated and placebo group.

There will be 2 weeks of active treatment, followed by 10 weeks of assessment without active treatment. During the 2-week active treatment phase, each subject will receive one IV bolus injection once a day for three times a week during these 2 weeks for a total of six injections. Subjects will be evaluated by UPDRS at screening, at baseline, and the ends of weeks 2 (at visit 6 after dosing), 6, and 12. The study duration for each subject is 12 weeks.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Parkinson's Disease
Intervention  ICMJE
  • Drug: GM608
    For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
    Other Names:
    • GM602
    • GM6
    • GM604
    • MNTF 6mer
  • Drug: Placebo Comparator
    For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
    Other Name: Bacteriostatic saline
Study Arms  ICMJE
  • Experimental: GM608
    4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
    Intervention: Drug: GM608
  • Placebo Comparator: Placebo comparator
    2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
    Intervention: Drug: Placebo Comparator
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 8, 2013)
6
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 2014
Actual Primary Completion Date July 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • with mild-moderate idiopathic PD diagnosed based on UK (United Kingdom) PD Brain Bank criteria.
  • Age > 30
  • Motor UPDRS Score ≥ 15
  • Hoehn & Yahr stage <3
  • Diagnosis of PD <10 years
  • Have fully completed informed consent form
  • May be on antiparkinsonian medications of an MAO-B (monoamine oxidase -B) inhibitor, an anticholinergic, or amantadine, but not levodopa or dopamine agonist

Exclusion Criteria:

  • Patients with atypical parkinsonism: such as suspected progressive supranuclear palsy (PSP), multiple system atrophy (MSA) or Corticobasal degeneration (CBD) and secondary parkinsonism such as normal-pressure hydrocephalus (NPH), drug-induced, or vascular parkinsonism.
  • Patients with uncertainty as to having classical Parkinson disease, such as those who might have scans without evidence of dopaminergic deficit (SWEDDs)
  • Patients not willing to give an informed consent
  • Patients who are on a dopaminergic medication (levodopa or dopamine agonist)
  • Presence of a medical or psychiatric comorbidity that can compromise participation in the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 30 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01850381
Other Study ID Numbers  ICMJE GBD 002
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Genervon Biopharmaceuticals, LLC
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Genervon Biopharmaceuticals, LLC
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Columbia University
Investigators  ICMJE
Principal Investigator: Stanley Fahn, MD Columbia University Medical Center/NY Presbyterian Hospital
PRS Account Genervon Biopharmaceuticals, LLC
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP